3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
31
Carcinoma, Hepatocellular
18
Neoplasms
13
Neoplasm Metastasis
13
Melanoma
13
Esophageal Neoplasms
12
Nasopharyngeal Carcinoma
10
Head and Neck Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Colorectal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Recurrence
7
Pancreatic Neoplasms
7
Rectal Neoplasms
6
Carcinoma, Renal Cell
6
Biliary Tract Neoplasms
6
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Interventions
Bevacizumab
7
Paclitaxel
3
vesencumab
2
atezolizumab
2
Immune Checkpoint Inhibitors
2
Carboplatin
2
1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
2
pertuzumab
1
peginterferon alfa-2a
1
parsatuzumab
1
ovcon 35
1
onartuzumab
1
obinutuzumab
1
ipatasertib
1
emactuzumab
1
Vitamin D
1
Trastuzumab
1
Rosiglitazone
1
Pemetrexed
1
Ipilimumab
1
Interferon alpha-2
1
HhAntag691
1
Grape Seed Extract
1
GDC-0623
1
GDC-0152
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Solid Cancers
×
Immune Checkpoint Inhibitors
×
Clear all
NCT07427186
2026-02-25
MINER2
Institut Claudius Regaud
Phase NA
Not yet recruiting
600 enrolled
NCT03514368
2026-02-19
MINER
Institut Claudius Regaud
Phase NA
Recruiting
770 enrolled